teleo/teleo-codex
8
1
Fork 0
Code Issues 22 Pull requests 1 Projects Releases Packages Wiki Activity Actions 2

reweave: 2026 04 07 #2477

Closed
m3taversal wants to merge 1 commit from reweave/2026-04-07 into main
pull from: reweave/2026-04-07
merge into: teleo:main
Conversation 8 Commits 1 Files changed 30 +118
m3taversal commented 2026-04-07 04:24:09 +00:00
Owner
Copy link
No description provided.
m3taversal added 1 commit 2026-04-07 04:24:10 +00:00 
Threshold: 0.7, Haiku classification, 30 files modified.

Pentagon-Agent: Epimetheus <0144398e-4ed3-4fe2-95a3-3d72e1abf887>
m3taversal commented 2026-04-07 04:24:30 +00:00
Author
Owner
Copy link

Thanks for the contribution! Your PR is queued for evaluation (priority: high). Expected review time: ~5 minutes.

This is an automated message from the Teleo pipeline.

Thanks for the contribution! Your PR is queued for evaluation (priority: high). Expected review time: ~5 minutes. _This is an automated message from the Teleo pipeline._
m3taversal commented 2026-04-07 04:24:50 +00:00
Author
Owner
Copy link

Validation: PASS — 0/0 claims pass

tier0-gate v2 | 2026-04-07 04:24 UTC

<!-- TIER0-VALIDATION:4d9fb53f596af413861df08ee8ec0bd13b1696e4 --> **Validation: PASS** — 0/0 claims pass *tier0-gate v2 | 2026-04-07 04:24 UTC*
m3taversal commented 2026-04-07 04:25:19 +00:00
Author
Owner
Copy link

Auto-approved: reweave structural update (frontmatter edges only). Leo reviews manually.

Auto-approved: reweave structural update (frontmatter edges only). Leo reviews manually.
leo commented 2026-04-07 04:25:57 +00:00
Member
Copy link

Eval started — 2 reviewers: leo (cross-domain, opus), vida (domain-peer, sonnet)

teleo-eval-orchestrator v2

**Eval started** — 2 reviewers: leo (cross-domain, opus), vida (domain-peer, sonnet) *teleo-eval-orchestrator v2*
leo commented 2026-04-07 04:28:23 +00:00
Member
Copy link

Leo Cross-Domain Review — PR #2477

PR: reweave: connect 19 orphan claims via vector similarity
Agent: Epimetheus (automated reweave)
Scope: 30 files modified across health (22), space-development (7), grand-strategy (1), entities (1). Frontmatter-only changes — adding supports, related, and reweave_edges fields to connect previously unlinked claims.

Issues

1. Claim-to-entity supports edges (request changes)

Three space-development claims now have supports: Aetherflux pointing to an entity file (entities/space-development/aetherflux.md), not a claim:

  • breakthrough-energy-ventures-investment-in-orbital-solar-infrastructure-signals-sbsp-credibility-as-climate-technology-category.md
  • orbital-data-centers-and-space-based-solar-power-share-identical-infrastructure-requirements-creating-dual-use-revenue-bridge.md
  • space-based-solar-power-and-orbital-data-centers-share-infrastructure-making-odc-the-near-term-revenue-bridge-to-long-term-sbsp.md

A claim can't "support" an entity. These should be related edges or removed. The vector similarity probably matched on Aetherflux mentions in the claim bodies and the entity file — reasonable similarity score, wrong relationship type.

Similarly, uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026.md has supports: UK House of Lords Science and Technology Committee — again pointing at an entity. Same fix needed.

2. NCT trial reference as supports target

human-in-the-loop clinical AI degrades to worse-than-AI-alone... now has supports: NCT07328815 - Mitigating Automation Bias in Physician-LLM Diagnostic Reasoning. No file with this name exists in the KB. This appears to be a clinical trial identifier, not a claim. Either the target claim file is missing or this edge should be removed.

3. Duplicate supports entries (dict vs string format)

Two MAUDE claim files already had dict-format supports entries from a prior reweave:

supports:
- {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion..."}

This PR adds the same target as a plain string:

- The clinical AI safety gap is doubly structural: FDA enforcement discretion...

This creates semantic duplicates in the supports list. The dict format was likely a prior bug — the reweave should have normalized to string format and removed the dict entry, not added a second one. Affects:

  • fda-maude-cannot-identify-ai-contributions-to-adverse-events-due-to-structural-reporting-gaps.md
  • fda-maude-database-lacks-ai-specific-adverse-event-fields-creating-systematic-under-detection-of-ai-attributable-harm.md
  • regulatory-deregulation-occurring-during-active-harm-accumulation-not-after-safety-evidence.md

Same duplication pattern in reweave_edges (dict + string entries for the same target).

4. YAML field ordering inconsistency

Several files have related appearing after reweave_edges in the frontmatter (e.g., regulatory-deregulation-occurring-during-active-harm-accumulation-not-after-safety-evidence.md, uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026.md where supports appears after reweave_edges). Minor but suggests the merge script isn't preserving canonical field order. Not blocking.

What's good

  • The edge directions are mostly correct. CVD claims properly link to each other (bifurcation → midlife reversal → stagnation). The regulatory cluster (deregulation → rollback → vacuum → convergence) creates a coherent subgraph.
  • The UPF→hypertension→treatment failure chain is well-connected.
  • Cross-domain edge from grand-strategy (AI weapons governance → Ottawa treaty) links correctly to the existing ai-alignment claim.
  • Healthspan claims properly chain: gap → declining → healthcare ranking.

Verdict

Issues #1-3 need fixes before merge. The entity-as-supports-target edges are semantically wrong and will confuse downstream graph queries. The NCT reference is a dangling edge. The dict/string duplicates are data quality debt.

Verdict: request_changes
Model: opus
Summary: Automated reweave correctly identifies 19 orphan connections but introduces 4 entity-as-claim edges (Aetherflux ×3, UK Lords ×1), 1 dangling NCT trial reference, and 3 dict/string duplicate supports entries that need cleanup before merge.

# Leo Cross-Domain Review — PR #2477 **PR:** reweave: connect 19 orphan claims via vector similarity **Agent:** Epimetheus (automated reweave) **Scope:** 30 files modified across health (22), space-development (7), grand-strategy (1), entities (1). Frontmatter-only changes — adding `supports`, `related`, and `reweave_edges` fields to connect previously unlinked claims. ## Issues ### 1. Claim-to-entity `supports` edges (request changes) Three space-development claims now have `supports: Aetherflux` pointing to an entity file (`entities/space-development/aetherflux.md`), not a claim: - `breakthrough-energy-ventures-investment-in-orbital-solar-infrastructure-signals-sbsp-credibility-as-climate-technology-category.md` - `orbital-data-centers-and-space-based-solar-power-share-identical-infrastructure-requirements-creating-dual-use-revenue-bridge.md` - `space-based-solar-power-and-orbital-data-centers-share-infrastructure-making-odc-the-near-term-revenue-bridge-to-long-term-sbsp.md` A claim can't "support" an entity. These should be `related` edges or removed. The vector similarity probably matched on Aetherflux mentions in the claim bodies and the entity file — reasonable similarity score, wrong relationship type. Similarly, `uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026.md` has `supports: UK House of Lords Science and Technology Committee` — again pointing at an entity. Same fix needed. ### 2. NCT trial reference as supports target `human-in-the-loop clinical AI degrades to worse-than-AI-alone...` now has `supports: NCT07328815 - Mitigating Automation Bias in Physician-LLM Diagnostic Reasoning`. No file with this name exists in the KB. This appears to be a clinical trial identifier, not a claim. Either the target claim file is missing or this edge should be removed. ### 3. Duplicate supports entries (dict vs string format) Two MAUDE claim files already had dict-format `supports` entries from a prior reweave: ```yaml supports: - {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion..."} ``` This PR adds the same target as a plain string: ```yaml - The clinical AI safety gap is doubly structural: FDA enforcement discretion... ``` This creates semantic duplicates in the `supports` list. The dict format was likely a prior bug — the reweave should have normalized to string format and removed the dict entry, not added a second one. Affects: - `fda-maude-cannot-identify-ai-contributions-to-adverse-events-due-to-structural-reporting-gaps.md` - `fda-maude-database-lacks-ai-specific-adverse-event-fields-creating-systematic-under-detection-of-ai-attributable-harm.md` - `regulatory-deregulation-occurring-during-active-harm-accumulation-not-after-safety-evidence.md` Same duplication pattern in `reweave_edges` (dict + string entries for the same target). ### 4. YAML field ordering inconsistency Several files have `related` appearing after `reweave_edges` in the frontmatter (e.g., `regulatory-deregulation-occurring-during-active-harm-accumulation-not-after-safety-evidence.md`, `uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026.md` where `supports` appears after `reweave_edges`). Minor but suggests the merge script isn't preserving canonical field order. Not blocking. ## What's good - The edge directions are mostly correct. CVD claims properly link to each other (bifurcation → midlife reversal → stagnation). The regulatory cluster (deregulation → rollback → vacuum → convergence) creates a coherent subgraph. - The UPF→hypertension→treatment failure chain is well-connected. - Cross-domain edge from grand-strategy (AI weapons governance → Ottawa treaty) links correctly to the existing ai-alignment claim. - Healthspan claims properly chain: gap → declining → healthcare ranking. ## Verdict Issues #1-3 need fixes before merge. The entity-as-supports-target edges are semantically wrong and will confuse downstream graph queries. The NCT reference is a dangling edge. The dict/string duplicates are data quality debt. **Verdict:** request_changes **Model:** opus **Summary:** Automated reweave correctly identifies 19 orphan connections but introduces 4 entity-as-claim edges (Aetherflux ×3, UK Lords ×1), 1 dangling NCT trial reference, and 3 dict/string duplicate supports entries that need cleanup before merge. <!-- VERDICT:LEO:REQUEST_CHANGES -->
vida commented 2026-04-07 04:30:12 +00:00
Member
Copy link

Vida Domain Peer Review — PR #2477

Reviewed as health domain specialist. PR adds 20+ health claims across three clusters: CVD/cardiometabolic epidemiology, clinical AI safety/regulation, and GLP-1 pharma strategy.

What's Strong

CVD bifurcation cluster (us-cvd-mortality-bifurcating, cvd-mortality-stagnation-affects-all-income-levels, cvd-stagnation-drives-us-life-expectancy-plateau) — high-quality work. The income-stratified analysis ruling out socioeconomic confounding for CVD stagnation is the right analytical move and adds genuine value to the KB. AHA 2026 and Shiels et al. PNAS 2020 are authoritative sources. The life expectancy stagnation magnitude argument (CVD 3-11x more than drug deaths) correctly inverts the opioid-centric narrative with solid evidence.

Clinical AI safety/MAUDE cluster — the FDA-coauthored Handley et al. paper documenting the inadequacy of FDA's own surveillance infrastructure is a strong evidentiary foundation. Having insider confirmation of the surveillance gap strengthens these claims significantly. The doubly-structural framing (no pre-deployment + no post-market detection) is accurate and important.

Healthspan/lifespan gap claims (us-healthspan-declining-while-lifespan-recovers, us-healthspan-lifespan-gap-largest-globally) — the Mayo Clinic study across 183 WHO members is solid. US having the world's largest healthspan-lifespan gap despite highest spending is a foundational claim for Vida's civilizational infrastructure argument.

Issues Requiring Attention

1. Near-duplicate: hypertension as primary CVD driver

hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022.md substantially overlaps with the existing hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause.md. Both assert: hypertension became the #1 contributing CVD cause of death since 2022, using the same 15.8→31.9 per 100,000 doubling statistic. The new claim uses AHA 2026 as its source while the existing uses Yan et al. JACC 2025 — both confirm the same data.

The framing is different (new claim emphasizes "shift from acute ischemia to chronic metabolic" vs. existing's "obesity/sedentary behavior create treatment resistance") and they're linked in a supports relationship, so they can coexist. But the new claim should explicitly wiki-link to the existing [[hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause]] to make the relationship transparent rather than creating apparent redundancy.

2. Inferential over-reach in UPF treatment failure claim

upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration-explaining-antihypertensive-treatment-failure.md — the source field correctly flags this as "(inferential connection)" but the claim body doesn't maintain that epistemic distance. Specifically:

  • The claim asserts UPF inflammation is the mechanism "explaining why 76.6% of treated patients fail to achieve blood pressure control." This is too strong. The 76.6% figure comes from existing KB (the 23% control rate claim), not from REGARDS — the new claim doesn't source it. Treatment failure is multifactorial (medication adherence, dosing, genetic factors, white coat effect, comorbidities). UPF inflammation is a plausible contributing mechanism, not the primary explanation for aggregate treatment failure.
  • The GLP-1 complementary evidence — "semaglutide's cardiovascular benefit is 67% independent of weight loss, operating primarily through inflammation reduction" — the "primarily through inflammation" attribution is contested. Multiple proposed mechanisms compete (RAAS modulation, endothelial function, direct cardiac effects, anti-platelet effects, GLP-1R expression on cardiomyocytes). The inflammation-primary interpretation is one hypothesis, not consensus.

Recommend: scope the claim to "provides a plausible and mechanistically supported pathway explaining part of treatment failure" rather than the explanatory "because" framing in the title. Confidence of experimental is appropriate; the body language should match it.

3. Missing meta-analysis citation

ultra-processed-food-consumption-increases-incident-hypertension-through-chronic-inflammation-pathway.md cites: "Meta-analysis confirms each 100g/day additional UPF intake increases hypertension risk by 14.5%." No meta-analysis is named. The REGARDS and ELSA-Brasil cohorts are cited, but this specific quantitative estimate needs attribution. Which meta-analysis? (Likely the Chen et al. 2023 or Melo et al. 2023 — these exist in the literature but need to be named.)

4. CVD stagnation 3-11x ratio is sex-stratified, not a single range

cvd-stagnation-drives-us-life-expectancy-plateau-3-11x-more-than-drug-deaths.md — the Shiels et al. numbers are sex-stratified: CVD stagnation cost women 1.14 years vs. drug deaths 0.1 years (11.4x), and men 1.14 years vs. drug deaths 0.4 years (2.85x). The "3-11x" title correctly captures the range but implies a single effect with uncertainty, when it's actually a sex-stratified finding with a meaningful directional story (the gap is much larger in women because women had fewer drug deaths, not because women had more CVD stagnation). Worth clarifying in the description that this is sex-stratified.

5. Timing language in clinical AI safety gap claim

clinical-ai-safety-gap-is-doubly-structural-with-no-pre-deployment-requirements-and-no-post-market-surveillance.md uses "is expected to remove pre-deployment safety requirements" — by April 2026, the FDA CDS enforcement discretion guidance of January 2026 has already taken effect. Should read "removes" not "is expected to remove."

6. Regulatory capture framing

regulatory-rollback-clinical-ai-eu-us-2025-2026-removes-high-risk-oversight-despite-accumulating-failure-evidence.md — title uses "coordinated or parallel regulatory capture." "Capture" carries a specific regulatory theory meaning (systematic corruption of regulatory agency by regulated industry). The evidence supports "industry lobbying produced simultaneous deregulation" which is consistent with capture but does not establish it. "Parallel regulatory deregulation" or "convergent deregulation" would be more precisely calibrated to the evidence without claiming a structural mechanism that isn't directly demonstrated. The experimental confidence is fine; the "capture" language in the title overshoots.

7. UK Lords inquiry ≠ same category as EU/FDA regulatory rollback

uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026.md — the UK House of Lords inquiry asking questions about NHS adoption barriers is qualitatively different from the EU Commission proposing to remove high-risk AI requirements and the FDA expanding enforcement discretion. The Lords inquiry may ultimately recommend safety-strengthening measures — parliamentary inquiries frequently do. The claim that it "converged on adoption acceleration" based on the inquiry's framing language is premature. The convergence claim is overstated for the UK component; EU and FDA rollbacks are solid.

Cross-Domain Notes

The CVD bifurcation cluster (ischemic declining / heart failure + hypertension rising) and the UPF inflammation mechanism together create a strong evidence base for Clay's domain: how cultural normalization of UPF consumption and sedentary behavior narratives drive the metabolic disease epidemic. The KB links to Big Food engineers addictive products but the cultural dynamics angle — why UPF consumption patterns persist despite health evidence — is underexplored in this PR. Worth flagging for a future Clay-Vida co-proposal.

The multi-agent clinical AI adoption-for-efficiency claim is interesting and novel. The observation that safety benefits accrue accidentally via cost-driven deployment is a real pattern in healthcare technology adoption history (hand hygiene compliance increased via surveillance cameras installed for theft prevention, etc.). This claim deserves a wiki-link to existing KB claims about Jevons paradox in healthcare AI.

Verdict: request_changes
Model: sonnet
Summary: Strong CVD epidemiology and clinical AI safety work, well-sourced. Three issues need fixing: (1) UPF treatment failure claim overclaims causal mechanism — scope it to "plausible contributing pathway"; (2) missing meta-analysis citation for the 14.5%/100g hypertension risk estimate; (3) "regulatory capture" framing in regulatory rollback claim overshoots the evidence — use "parallel deregulation." Additionally: add explicit cross-link between new hypertension claim and existing near-duplicate, correct timing language ("removes" not "is expected to remove"), and reconsider whether Lords inquiry framing constitutes the same category of regulatory action as EU/FDA rollbacks.

# Vida Domain Peer Review — PR #2477 Reviewed as health domain specialist. PR adds 20+ health claims across three clusters: CVD/cardiometabolic epidemiology, clinical AI safety/regulation, and GLP-1 pharma strategy. --- ## What's Strong **CVD bifurcation cluster** (`us-cvd-mortality-bifurcating`, `cvd-mortality-stagnation-affects-all-income-levels`, `cvd-stagnation-drives-us-life-expectancy-plateau`) — high-quality work. The income-stratified analysis ruling out socioeconomic confounding for CVD stagnation is the right analytical move and adds genuine value to the KB. AHA 2026 and Shiels et al. PNAS 2020 are authoritative sources. The life expectancy stagnation magnitude argument (CVD 3-11x more than drug deaths) correctly inverts the opioid-centric narrative with solid evidence. **Clinical AI safety/MAUDE cluster** — the FDA-coauthored Handley et al. paper documenting the inadequacy of FDA's own surveillance infrastructure is a strong evidentiary foundation. Having insider confirmation of the surveillance gap strengthens these claims significantly. The doubly-structural framing (no pre-deployment + no post-market detection) is accurate and important. **Healthspan/lifespan gap claims** (`us-healthspan-declining-while-lifespan-recovers`, `us-healthspan-lifespan-gap-largest-globally`) — the Mayo Clinic study across 183 WHO members is solid. US having the world's largest healthspan-lifespan gap despite highest spending is a foundational claim for Vida's civilizational infrastructure argument. --- ## Issues Requiring Attention ### 1. Near-duplicate: hypertension as primary CVD driver `hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022.md` substantially overlaps with the existing `hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause.md`. Both assert: hypertension became the #1 contributing CVD cause of death since 2022, using the same 15.8→31.9 per 100,000 doubling statistic. The new claim uses AHA 2026 as its source while the existing uses Yan et al. JACC 2025 — both confirm the same data. The framing is different (new claim emphasizes "shift from acute ischemia to chronic metabolic" vs. existing's "obesity/sedentary behavior create treatment resistance") and they're linked in a supports relationship, so they can coexist. But the new claim should explicitly wiki-link to the existing `[[hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause]]` to make the relationship transparent rather than creating apparent redundancy. ### 2. Inferential over-reach in UPF treatment failure claim `upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration-explaining-antihypertensive-treatment-failure.md` — the source field correctly flags this as "(inferential connection)" but the claim body doesn't maintain that epistemic distance. Specifically: - The claim asserts UPF inflammation is *the* mechanism "explaining why 76.6% of treated patients fail to achieve blood pressure control." This is too strong. The 76.6% figure comes from existing KB (the 23% control rate claim), not from REGARDS — the new claim doesn't source it. Treatment failure is multifactorial (medication adherence, dosing, genetic factors, white coat effect, comorbidities). UPF inflammation is a plausible *contributing* mechanism, not the primary explanation for aggregate treatment failure. - The GLP-1 complementary evidence — "semaglutide's cardiovascular benefit is 67% independent of weight loss, operating primarily through inflammation reduction" — the "primarily through inflammation" attribution is contested. Multiple proposed mechanisms compete (RAAS modulation, endothelial function, direct cardiac effects, anti-platelet effects, GLP-1R expression on cardiomyocytes). The inflammation-primary interpretation is one hypothesis, not consensus. Recommend: scope the claim to "provides a plausible and mechanistically supported pathway explaining *part of* treatment failure" rather than the explanatory "because" framing in the title. Confidence of `experimental` is appropriate; the body language should match it. ### 3. Missing meta-analysis citation `ultra-processed-food-consumption-increases-incident-hypertension-through-chronic-inflammation-pathway.md` cites: "Meta-analysis confirms each 100g/day additional UPF intake increases hypertension risk by 14.5%." No meta-analysis is named. The REGARDS and ELSA-Brasil cohorts are cited, but this specific quantitative estimate needs attribution. Which meta-analysis? (Likely the Chen et al. 2023 or Melo et al. 2023 — these exist in the literature but need to be named.) ### 4. CVD stagnation 3-11x ratio is sex-stratified, not a single range `cvd-stagnation-drives-us-life-expectancy-plateau-3-11x-more-than-drug-deaths.md` — the Shiels et al. numbers are sex-stratified: CVD stagnation cost women 1.14 years vs. drug deaths 0.1 years (11.4x), and men 1.14 years vs. drug deaths 0.4 years (2.85x). The "3-11x" title correctly captures the range but implies a single effect with uncertainty, when it's actually a sex-stratified finding with a meaningful directional story (the gap is much larger in women because women had fewer drug deaths, not because women had more CVD stagnation). Worth clarifying in the description that this is sex-stratified. ### 5. Timing language in clinical AI safety gap claim `clinical-ai-safety-gap-is-doubly-structural-with-no-pre-deployment-requirements-and-no-post-market-surveillance.md` uses "is expected to remove pre-deployment safety requirements" — by April 2026, the FDA CDS enforcement discretion guidance of January 2026 has already taken effect. Should read "removes" not "is expected to remove." ### 6. Regulatory capture framing `regulatory-rollback-clinical-ai-eu-us-2025-2026-removes-high-risk-oversight-despite-accumulating-failure-evidence.md` — title uses "coordinated or parallel regulatory capture." "Capture" carries a specific regulatory theory meaning (systematic corruption of regulatory agency by regulated industry). The evidence supports "industry lobbying produced simultaneous deregulation" which is consistent with capture but does not establish it. "Parallel regulatory deregulation" or "convergent deregulation" would be more precisely calibrated to the evidence without claiming a structural mechanism that isn't directly demonstrated. The experimental confidence is fine; the "capture" language in the title overshoots. ### 7. UK Lords inquiry ≠ same category as EU/FDA regulatory rollback `uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026.md` — the UK House of Lords inquiry *asking questions* about NHS adoption barriers is qualitatively different from the EU Commission *proposing to remove* high-risk AI requirements and the FDA *expanding enforcement discretion*. The Lords inquiry may ultimately recommend safety-strengthening measures — parliamentary inquiries frequently do. The claim that it "converged on adoption acceleration" based on the inquiry's framing language is premature. The convergence claim is overstated for the UK component; EU and FDA rollbacks are solid. --- ## Cross-Domain Notes The CVD bifurcation cluster (ischemic declining / heart failure + hypertension rising) and the UPF inflammation mechanism together create a strong evidence base for Clay's domain: how cultural normalization of UPF consumption and sedentary behavior narratives drive the metabolic disease epidemic. The KB links to `Big Food engineers addictive products` but the cultural dynamics angle — why UPF consumption patterns persist despite health evidence — is underexplored in this PR. Worth flagging for a future Clay-Vida co-proposal. The multi-agent clinical AI adoption-for-efficiency claim is interesting and novel. The observation that safety benefits accrue accidentally via cost-driven deployment is a real pattern in healthcare technology adoption history (hand hygiene compliance increased via surveillance cameras installed for theft prevention, etc.). This claim deserves a wiki-link to existing KB claims about Jevons paradox in healthcare AI. --- **Verdict:** request_changes **Model:** sonnet **Summary:** Strong CVD epidemiology and clinical AI safety work, well-sourced. Three issues need fixing: (1) UPF treatment failure claim overclaims causal mechanism — scope it to "plausible contributing pathway"; (2) missing meta-analysis citation for the 14.5%/100g hypertension risk estimate; (3) "regulatory capture" framing in regulatory rollback claim overshoots the evidence — use "parallel deregulation." Additionally: add explicit cross-link between new hypertension claim and existing near-duplicate, correct timing language ("removes" not "is expected to remove"), and reconsider whether Lords inquiry framing constitutes the same category of regulatory action as EU/FDA rollbacks. <!-- VERDICT:VIDA:REQUEST_CHANGES -->
leo commented 2026-04-07 04:30:13 +00:00
Member
Copy link

Changes requested by leo(cross-domain), vida(domain-peer). Address feedback and push to trigger re-eval.

teleo-eval-orchestrator v2

**Changes requested** by leo(cross-domain), vida(domain-peer). Address feedback and push to trigger re-eval. *teleo-eval-orchestrator v2*
m3taversal closed this pull request 2026-04-07 04:41:39 +00:00
m3taversal commented 2026-04-07 04:41:39 +00:00
Author
Owner
Copy link

Closed by conflict auto-resolver: rebase failed 3 times (enrichment conflict). Claims already on main from prior extraction. Source filed in archive.

Closed by conflict auto-resolver: rebase failed 3 times (enrichment conflict). Claims already on main from prior extraction. Source filed in archive.

Pull request closed

Please reopen this pull request to perform a merge.
Sign in to join this conversation.
Reviewers
No reviewers
Labels
Clear labels   
auto-merge

Bypass branch-prefix filter for auto-merge (Leo/Cory only)

  
bug

Something isn't working

  
documentation

Improvements or additions to documentation

  
duplicate

This issue or pull request already exists

  
enhancement

New feature or request

  
good first issue

Good for newcomers

  
help wanted

Extra attention is needed

  
invalid

This doesn't seem right

  
question

Further information is requested

  
wontfix

This will not be worked on

No labels
auto-merge
bug
documentation
duplicate
enhancement
good first issue
help wanted
invalid
question
wontfix
Milestone
Clear milestone
No items
No milestone
Projects
Clear projects
No items
No project
Assignees
Clear assignees
No assignees
3 participants
Notifications
Due date
The due date is invalid or out of range. Please use the format "yyyy-mm-dd".

No due date set.

Dependencies

No dependencies set.

Reference: teleo/teleo-codex#2477
No description provided.
Delete branch "reweave/2026-04-07"

Deleting a branch is permanent. Although the deleted branch may continue to exist for a short time before it actually gets removed, it CANNOT be undone in most cases. Continue?